Results 141 to 150 of about 756,250 (282)

The burden of COVID‐19 in hospitalized people with diabetes mellitus in Brazil: Insights from four years of the pandemic

Diabetic Medicine, EarlyView.
Abstract Aims Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is more severe in people with diabetes mellitus due to immune dysfunction, exacerbated inflammation and increased risk of co‐morbidities and mortality.
Taís Mendes Camargo, Bianca Aparecida Siqueira, Luiz Felipe Azevedo Marques, Lucas Silva Mello, Fernando Augusto Lima Marson   +4 more
wiley   +1 more source

Inhibition of RAS in diabetic nephropathy

International Journal of Nephrology and Renovascular Disease, 2015
Rabi Yacoub, Kirk N Campbell Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY, USA Abstract: Diabetic kidney disease (DKD) is a progressive proteinuric renal disorder in patients with type 1 or type 2
Yacoub R, Campbell KN
doaj  

Multisystem developmental abnormalities and insulin resistance in ADTKD‐HNF1B with the p.E105K variant: A clinical conundrum

Diabetic Medicine, EarlyView.
Abstract Aims HNF1B variants cause autosomal dominant tubulointerstitial kidney disease (ADTKD‐HNF1B), but the phenotypic spectrum of variants of uncertain significance (VUS) remains incompletely defined. We aimed to characterise the multisystem phenotype associated with the HNF1B p.E105K variant and to examine the mechanism underlying insulin ...
YunZe Wang, KangChun Xu, PengFei Liu, Bin Wang, Yan Yang, ShanZhai Wei   +5 more
wiley   +1 more source

Early sodium‐glucose co‐transporter 2 inhibitor initiation is associated with improved cardiovascular outcomes in type 2 diabetes and acute coronary syndrome

Diabetic Medicine, EarlyView.
Abstract Aims Sodium‐glucose co‐transporter 2 inhibitors have demonstrated cardiovascular benefits in individuals with type 2 diabetes mellitus, but the optimal timing of initiation in those with acute coronary syndrome is not known. This study aims to assess if early therapy at discharge is superior to delayed or no therapy in reduction in major ...
Muhammad Usman Shah, Joanna Kate Ward, Alun Roebuck, Bala Srinivasan, Paul Edward Squires, Claire Elizabeth Hills, Maxime Inghels, Kelvin Lee   +7 more
wiley   +1 more source

Real‐world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide

Diabetic Medicine, EarlyView.
Abstract Background Obesity and type 2 diabetes mellitus (T2DM) accelerate chronic kidney disease (CKD) progression. Tirzepatide, a dual glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonist, has demonstrated metabolic and potential renoprotective benefits in clinical trials.
Jack E. Carruthers, Xi Yan Ooi, Dawn Goodall, Jo Reed, Rachna Bedi, Adrian McGrath, Michelle Willicombe, Parizad Avari, Andrew H. Frankel   +8 more
wiley   +1 more source

Renin inhibitors versus angiotensin receptor blockers for primary hypertension. [PDF]

Cochrane Database Syst Rev
Wang GM, Li LJ, Fan L, Xu M, Tang WL, Wright JM.   +5 more
europepmc   +1 more source

Kidney Outcomes With GLP‐1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real‐World Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To compare kidney outcomes after GLP‐1 receptor agonists (RA) or tirzepatide (GLP‐1/GIP RAs) versus finerenone initiation in adults with Type 2 diabetes (T2D) and moderate chronic kidney disease (CKD). Methods In a retrospective TriNetX global network study (July 2021–November 2025), adults with T2D and CKD stages 3–4 initiating GLP‐1/GIP ...
Dvora R. Sehtman‐Shachar, Alisa Fishkin, Gil Leibowitz, Ofri Mosenzon, Meir Schechter, Genya Aharon‐Hananel   +5 more
wiley   +1 more source

Haemodynamic effects of acute and chronic renin inhibition in marmosets

, 1989
We have developed marmoset models for the in vivo evaluation of primate-specific inhibitors of human renin. After acute intravenous administration to normotensive sodium-depleted marmosets, renin inhibitors of different structural types induced a maximum
Gulati, N., Baum, H. P., Jobber, R. A., Wood, J. M., Neisius, D., Hofbauer, K. G., Forgiarini, P.   +6 more
core  

Changes in Metabolic and Blood Pressure Outcomes With Semaglutide Across Chronic Kidney Disease Stages: A Post Hoc Analysis of the FLOW Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess changes in glycated haemoglobin (HbA1c), body weight, and systolic/diastolic blood pressure (SBP/DBP) by chronic kidney disease (CKD) and albuminuria categories in a post hoc analysis of FLOW, an international, double‐blind, randomized, phase 3b clinical trial of adults with CKD and Type 2 diabetes (T2D).
Allon N. Friedman, Jan Basile, Robert Busch, David M. Charytan, Kenneth W. Mahaffey, Sherif Mehanna, Søren Rasmussen, Peter Rossing, Caroline Swift, Katherine R. Tuttle, Richard Pratley   +10 more
wiley   +1 more source

Cardiovascular Outcomes of Insulin Degludec Versus Insulin Glargine in Trial‐Eligible and Ineligible Populations: A DEVOTE‐Inspired Target Trial Emulation Using the Swedish National Diabetes Register

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare cardiovascular outcomes associated with the initiation of insulin degludec versus insulin glargine using a target trial emulation approach in nationwide real‐world data. Materials and Methods We conducted a nationwide observational cohort study using Swedish health registers, including the National Diabetes Register ...
Thomas Nyström, Jens Michelsen, Henrik Imberg, Sara Hallström, Viktor Tasselius, Anna Norhammar, Max Petzold, Julia K. Mader, Pratik Choudhary, Manal K. Elzalabany, Jonathan Valabhji, Shivani Misra, Safoora Gharibzadeh, Puriya Daniel Würtz Yazdanfard, Kathrine Kold Sørensen, Christian Torp‐Pedersen, Marcus Lind   +16 more
wiley   +1 more source